Breast cancer | Flatiron Health

Carter, GC, Sheffield, KM, Gossai, A, Huang, Y, Zhu, YE, Bowman, L, Smyth, EN, Mathur, R, Cohen, AB, Rasmussen, E, Balakrishna, S, Guimaraes, CM, Rybowski, S, Seidman, AD

May 2021

Manuscript

Current Medical Research and Opinion

Flatiron-authored

Patient with lobular carcinoma of the breast and activating AKT1 E17K variant →

Trivedi, H, Hamdani, O, Thomas, B, Richard, J, Shah, K, Raskina, K, Zhang, L, Madigan, A, Fox, M, Wander, S, Frigault, M, Alexander, BM, Srkalovic, G

April 2021

Manuscript

Acta Medica Academia

Clinical trial participation in real-world patients with metastatic breast cancer: disparities and barriers →

Tan, R, Wang, R, Abbass, IM, Cassoli, L, Mitchell, EP

April 2021

Abstract

AACR Annual Meeting

Comprehensive genomic profiling in breast cancer: patterns and results from a clinico-genomic database →

Rody, A, Chaudhary, N, Craggs, C, Debiasi, M, Erb, G, Fisher, V, McCusker, M, Snow, T, Losada, MV, Luhn, P

April 2021

Abstract

AACR Annual Meeting

Flatiron-authored

Comparative effectiveness of first-line palbociclib plus letrozole versus letrozole alone for HR+/HER2−metastatic breast cancer in US real-world clinical practice →

DeMichele, A, Cristofanilli, M, Brufsky, A, Liu, X, Mardekian, J, McRoy, L, Layman, RM, Emir, B, Torres, M, Rugo, HS, Finn, RS

March 2021

Manuscript

Breast Cancer Research

The incidence of thrombocytopenia in adult patients receiving chemotherapy for solid tumors or hematologic malignancies →

Shaw, JL, Nielson, CM, Park, JK, Marongiu, A, Soff, GA

February 2021

Manuscript

European Journal of Haematology

Patterns of treatment with everolimus exemestane in hormone receptor-positive HER2-negative metastatic breast cancer in the era of targeted therapy →

Rozenblit, M, Mun, S, Soulos, PR, Adelson, KB, Pusztai, L, Mougalian, SS

January 2021

Manuscript

Breast Cancer Research

Association of Pertuzumab, Trastuzumab, and Docetaxel combination therapy with overall survival in patients with metastatic breast cancer →

Ramagopalan, S, Pisoni, R, Rathore, LS, Ray, J, Sammon, C

January 2021

Manuscript

JAMA Open

Understanding the impact of assessment frequency on the study of adverse effects using oncology electronic health records →

Liang, Q, Zhang, Q, Rosic, A, Bowser, B, Tharani, S, Brake, SD, Magee, K, Parrinello, CM, Baxi, SS

November 2020

Abstract

EU ISPOR

Flatiron-authored

Comparative effectiveness of trastuzumab emtansine versus lapatinib plus capecitabine for HER2+ metastatic breast cancer →

Ramagopalan, S, Pisoni, R, Zenin, A, Rathore, LS, Ray, J, Sammon, C

October 2020

Manuscript

Journal of Comparative Effectiveness Research

Real-world outcomes among HER2+ metastatic breast cancer patients with brain metastases →

Lindegger, N, Ike, C, Schwartz, NRM, Surinach, A, Liu, Y, Forero-Torres, A, DeBusk, K

September 2020

Abstract

ESMO Annual Congress

Real-world survival of heavily pretreated patients with refractory HR+, HER2-metastatic breast cancer receiving single-agent chemotherapy-A comparison with MONARCH 1 →

Rugo, HS, Dieras, V, Cortes, J, Patt, D, Wildiers, H, O'Shaughnessy, J, Zamora, E, Yardley, DA, Carter, GC, Sheffield, KM, Li, L, Andre, VAM, Derbyshire, RE, Li, XI, Frenzel, M, Huang, Y, Dickler, MN, Tolaney, SM

August 2020

Manuscript

Breast Cancer Research and Treatment

Prior treatment time impacts survival outcomes in metastatic breast cancer →

Rocque, GB, Gilbert, A, Williams, CP, Kenzik, KM, Nakhmani, A, Kandhare, PG, Bhatia, S, Burkard, ME, Azuero, A

June 2020

Manuscript

JCO Clinical Cancer Informatics

Pan-cancer profiling of the effect of biopsied site on tumor mutational burden measurements in a real-world data cohort →

Papillon-Cavanagh, S, Gao, C, Han, GC, Walsh, AM

May 2020

Abstract

AACR Annual Meeting

12-month uptake of PD-L1 testing and atezolizumab + nab-paclitaxel treatment in metastatic triple-negative breast cancer following accelerated FDA-approval in the United States →

Emens, LA, Craggs, C, Debiasi, M, Kent, M, Luhn, P, Hamilton, EP

May 2020

Abstract

ASCO Annual Meeting

Concordance of real-world versus conventional progression-free survival from a phase 3 trial of endocrine therapy as first-line treatment for metastatic breast cancer →

Bartlett, CH, Mardekian, J, Cotter, MJ, Huang, X, Zhang, Z, Parrinello, CM, Bourla, AB

April 2020

Manuscript

PLoS One

Flatiron-authored

Letting the GENIE out of its bottle: examining the potential of real-world clinico-genomic data →

Castellanos, EH, Baxi, SS

April 2020

Manuscript

Cancer Discovery

Flatiron-authored

Prognostic significance of cancer patient reported outcomes in cancer →

Kerrigan, KC, Patel, SB, Halland, B, Ose, D, Chalmers, AW, Haydell, T, Meropol, NJ, Akerley, WL

January 2020

Manuscript

Journal of Oncology Practice

Flatiron-authored

Utility of novel clinico-genomic data to understand patient characteristics, treatments, and outcomes according to PIK3CA mutation status among hormone receptor positive metastatic breast cancer patients →

Downer, MK, Lambert, P, Mahrus, S, Hutchinson, KE, Luhn, P, Schutzman, JL

January 2020

Abstract

AACR Special Meeting

Real-world predictors of first-line treatment and descriptive outcomes in patients with HR+/HER2- metastatic breast cancer in the US →

Downer, MK, Jhaveri, K, Bardia, A, Loi, S, Kent, M, Luhn, P, Humke, EW

December 2019

Abstract

San Antonio Breast Cancer Symposium

Initial real-world treatment patterns and outcomes of abemaciclib for the treatment of HR+HER2-metastatic breast cancer →

Carter, GC, Sheffield, KM, Gossai, A, Huang, Y, Zhu, YE, Bowman, L, Smyth, EN, Mathur, R, Cohen, AB, Baxi, SS, Rybowski, S, Chong, AL, Seidman, AD

December 2019

Abstract

San Antonio Breast Cancer Symposium

Flatiron-authored

Treatment sequencing of HR+/HER2- metastatic breast cancer (mBC) patients based on PIK3CA alteration status – a retrospective analysis of a US clinicogenomics database →

Turner, SJ, Wang, I, Park, J, Kanakamedala, H, Lorenzo, I

December 2019

Abstract

San Antonio Breast Cancer Symposium

Systemic corticosteroid use in patients with metastatic triple-negative breast cancer treated with first-line therapy in the United States →

Downer, MK, Luhn, P, Miles, D, Kent, M, Russell, K, O'Shaughnessy, J

December 2019

Abstract

San Antonio Breast Cancer Symposium

Visualization of the relationship between survival and sequential treatments in metastatic breast cancer →

Rocque, GB, Gilbert, A, Williams, CP, Nakhmani, A, Kandhare, PG, Azuero, A, Bhatia, S, Kenzik, KM, Burkard, ME

December 2019

Abstract

San Antonio Breast Cancer Symposium

Cardiac events in patients with HER2-positive metastatic breast cancer who have low left ventricular ejection fraction prior to initiating treatment with ado-trastuzumab emtansine: a retrospective cohort study using electronic health record data →

Sanglier, T, Shim, J, Liu, H, Song, C, Smitt, M, Flahavan, EM

December 2019

Abstract

San Antonio Breast Cancer Symposium

Use of pertuzumab in combination with taxanes for HER2+ metastatic breast cancer: analysis of U.S. electronic health records →

Polito, L, Shim, J, Du Toit, YD, Do, T, Knott, A, Sanglier, T

December 2019

Abstract

San Antonio Breast Cancer Symposium

Patterns of treatment with everolimus and exemestane in hormone receptor positive HER2 negative metastatic breast cancer in the era of targeted therapy →

Rozenblit, M, Pusztai, L, Adelson, KB, Mougalian, SS

December 2019

Abstract

San Antonio Breast Cancer Symposium

Overall survival for first-line palbociclib plus letrozole alone for HR+/HER2- metastatic breast cancer patients in US real-world clinical practice →

DeMichele, A, Cristofanilli, M, Brufsky, A, Liu, X, Mardekian, J, McRoy, L, Layman, RM, Rugo, HS, Finn, RS

December 2019

Abstract

San Antonio Breast Cancer Symposium

Characteristics of MBC patients receiving first line treatments in the US real-world setting in the era of CDK4/6 inhibitors →

Brufsky, A, Chen, C, Mardekian, J, Liu, X, McRoy, L, Torres, M

December 2019

Abstract

San Antonio Breast Cancer Symposium

Palbociclib plus an aromatase inhibitor as first-line therapy for metastatic breast cancer in US clinical practices: Real-world progression-free survival analysis →

Torres, M, Liu, X, Mardekian, J, McRoy, L

October 2019

Abstract

ESMO Annual Congress

Comparative effectiveness of palbociclib plus letrozole vs letrozole for metastatic breast cancer in US real-world clinical practices →

Layman, RM, Liu, X, Mardekian, J, McRoy, L

September 2019

Abstract

ESMO Annual Congress

Use of trastuzumab emtansine (T-DM1) after pertuzumab + trastuzumab (PH) in patients with HER2-positive metastatic breast cancer (mBC): Challenges in assessing effectiveness of treatment sequencing in the real world →

Sanglier, T, Fabi, A, Flores, C, Flahavan, EM, Lindegger, N, Montemurro, F

September 2019

Abstract

ESMO Annual Congress

Real-world evidence of male breast cancer (BC) patients treated with palbociclib (PAL) in combination with endocrine therapy (ET) →

Bartlett, CH, Mardekian, J, Yu-Kite, M, Cotter, MJ, Kim, S, Decembrino, J, Snow, T, Carson, KR, Rockland, JM, Kraus, AL, Wilner, KD, Oharu, N, Schnell, P, Lu, D, Tursi, J

September 2019

Abstract

Annual Metastatic Breast Cancer Conference

Flatiron-authored

Metastatic breast cancer sub-type classification using biomarker and treatment information in electronic health records →

Craggs, C, Flahavan, EM, Surinach, A, Kent, M, Sanglier, T

August 2019

Abstract

International Conference on Pharmacoepidemiology & Therapeutic Risk Management (ICPE)

Comparative effectiveness of first-line nab-paclitaxel versus paclitaxel monotherapy in triple-negative breast cancer →

Luhn P, Chui SY, Hsieh AF, Yi J, Mecke A, Bajaj PS, Hasnain W, Falgas A, Ton TG, Kurian AW

August 2019

Manuscript

Journal of Comparative Effectiveness Research

Affordable Care Act Medicaid expansion impact on racial disparities in time to cancer treatment →

Adamson B, Cohen AB, Estevez M, Magee K, Williams E, Gross CP, Meropol NJ, Davidoff AJ

June 2019

Abstract

ASCO Annual Meeting

Flatiron-authored

Real-world evidence of male breast cancer patients treated with palbociclib in combination with endocrine therapy →

Bartlett CH, Mardekian J, Yu-Kite M, Cotter MJ, Kim S, Decembrino J, Snow T, Carson KR, Rockland JM, Kraus AL, Wilner KD, Oharu N, Schnell P, Lu D, Tursi J

June 2019

Abstract

ASCO Annual Meeting

Flatiron-authored

A real-world evidence study of CDK4/6 inhibitor treatment patterns and outcomes in metastatic breast cancer by gBRCA mutation status →

McLaurin K, Dalvi T, Collins JM, Nordstrom BL, McCutcheon S, Bennett JC, Murphy BR, Singhal PK, Briceno JM

June 2019

Abstract

ASCO Annual Meeting

Real-world effectiveness of palbociclib in combination with an aromatase inhibitor as first-line therapy in metastatic breast cancer →

Liu X, Mardekian J, McRoy L

June 2019

Abstract

ASCO Annual Meeting

Machine Learning Model for Cancer Biomarker Identification in Electronic Health Records →

Ambwani G, Cohen A, Estévez M, Singh N, Adamson B, Nussbaum N, Birnbaum B

May 2019

Abstract

ISPOR Annual Meeting

Flatiron-authored

Clinical outcomes, treatment patterns, and health resource utilization among metastatic breast cancer patients with germline BRCA1/2 mutation: A real-world retrospective study →

Quek RGW, Mardekian J

January 2019

Manuscript

Advances in Therapy

Influence of Prognostic Factors on Outcomes Among Metastatic Breast Cancer Patients Treated with CDK4&6 Inhibitors in Routine Clinical Practice →

Saverno KR, Carter GC, Li L, Battiato LA, Huang Y-J, Smyth EN, Price GL, Sheffield KM, Baxi SS, Kuk D, Seidman AD

December 2018

Abstract

San Antonio Breast Cancer Symposium

Flatiron-authored

Outcomes in patients (pts) with metastatic triple-negative breast cancer (mTNBC) treated in second line (2L) in the US real-world setting →

Luhn P, O'Hear C, Ton TG, Hsieh A, Yi J, Chang C-W, Funke R, Kurian A

December 2018

Abstract

San Antonio Breast Cancer Symposium

A real world evidence study of BRCA mutations and survival in HER2-negative breast cancer →

Dalvi T, McLaurin K, Briceno J, Nordstrom B, Bennett J, Hettle R, Murphy B, Collins J, McCutcheon S

December 2018

Abstract

San Antonio Breast Cancer Symposium

Time to treatment discontinuation of second-line fulvestrant monotherapy for HR+/HER2− metastatic breast cancer in the real-world setting →

Luhn P, O'Hear C, Ton TG, Sanglier T, Hsieh A, Oliveri D, Chuo J, Xiao Y, Emens L

December 2018

Abstract

San Antonio Breast Cancer Symposium

Real-world survival of heavily pretreated patients with refractory HR+, HER2- metastatic breast cancer receiving single-agent chemotherapy – A comparison with MONARCH 1 →

Rugo H, Dieras V, Cortes J, Patt D, Wildiers H, O'Shaughnessy J, Zamora E, Yardley DY, Carter GC, Sheffield KM, Li L, Andre VA, Derbyshire RE, Li XI, Frenzel M, Huang Y-J, Dickler MN, Tolaney SM

December 2018

Abstract

San Antonio Breast Cancer Symposium

Clinical Outcomes, Treatment Patterns and Health Resource Utilization (HRU) Among Metastatic Breast Cancer (MBC) Patients (pts) with Germline BRCA Mutation (gBRCAm) →

Quek R

October 2018

Abstract

ESMO Annual Congress

Comparative Effectiveness of Nab-Paclitaxel vs. Paclitaxel Monotherapy as First-Line (1L) Treatment of Metastatic Triple-Negative Breast Cancer (mTNBC) in US Clinical Practice →

Luhn T

October 2018

Abstract

ESMO Annual Congress

Quantifying the Impact of Mortality Underreporting on Analyses of Overall Survival →

Bretscher MT, Sanglier T

August 2018

Abstract

International Conference on Pharmacoepidemiology & Therapeutic Risk Management (ICPE)

Development and Validation of a High-Quality Composite Real-World Mortality Endpoint →

Curtis MD, Griffith S, Tucker M, Taylor M, Capra W, Carrigan G, Holzman B, Torres AZ, You P, Arnieri B, Abernethy AP

June 2018

Abstract

Academy Health Annual Research Meeting

Flatiron-authored

Real-World (RW) Characteristics, Treatment (tx) Patterns, and Overall Survival (OS) in US Patients (pts) with Metastatic Breast Cancer (mBC) and CNS Metastases (CNS mets) →

Shewade A, Fu-Chi Hsieh A, Mani A, Al-Sakaff N, Sanglier T, Taylor M, Heinzmann D

June 2018

Abstract

ASCO Annual Meeting

Risk Stratification Using Patient-Reported Outcomes (PROs) in Patients (pts) with Advanced Cancer →

Patel SB, Haaland B, Ose D, Haydell T, Martineau J, Dunson W, Chalmers AW, Cannon L, Kissell B, Meropol N, Akerley W

June 2018

Abstract

ASCO Annual Meeting

Flatiron-authored

Real-World Clinical Outcomes and Treatment Patterns among Metastatic Breast Cancer (MBC) Patients with Germline BRCA Mutation (gBRCAmut) →

Quek R, Mardekian J

June 2018

Abstract

ASCO Annual Meeting

Impact of Flexible Assessment Schedules on Treatment Effect Bias in Pragmatic Clinical Trials →

Bourla A, Sweeney E, Parrinello CM, Abernethy AP, Griffith S

June 2018

Abstract

ASCO Annual Meeting

Flatiron-authored

Prevalence of Microsatellite Instability and Association with Pembrolizumab (P) Usage in a Real-World Clinico-Genomic Database →

O'Connell C, Backenroth D, Singal G, Agarwala V, Li G, Kaushik G, Alpha-Cobb G, Kao CK, Miller V, Abernethy AP, Carson K

June 2018

Abstract

ASCO Annual Meeting

Flatiron-authored

ICD-Coded Information on Sites of Metastasis in Oncology Real-World Data is Specific But Not Sensitive →

Parrinello CM, Seidl-Rathkopf K, Bennette CS, Bourla A, Nussbaum N, Carson K, Abernethy AP

May 2018

Abstract

ISPOR Annual Meeting

Flatiron-authored

Use of Cancer Immunotherapies in the Real-World in the Setting of Microsatellite Instability →

Agarwala V, Gossai A, Singal G, O'Connell C, Li G, Kao K, Bourque D, Feuchtbaum D, Nunnally A, Frampton G, Ali S, Abernethy AP, Kramarz S, Trabucco SE

January 2018

Abstract

ASCO-SITC Clinical Immuno-Oncology Symposium

Flatiron-authored